Pediatric CancerVIDEO-PEDSNCT06786104
Video Inspired Discussions About Ethical Outcomes in Pediatrics
A study testing VIDEO-PEDS, VIDEO-PEDS pilot and Focus Group in people with Pediatric Cancer, run by Massachusetts General Hospital at 4 sites in United States.
Trial summary
The goal of this clinical trial is to learn if the VIDEO-PEDS intervention works to improve Goals of Care communication between clinicians and parents of children with cancer. The main questions it aims to answer are: Does the intervention improve Goals of Care documentation? Does it improve patient outcomes… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Pediatric Cancer
- What is being tested?
- VIDEO-PEDS, VIDEO-PEDS pilot and Focus Group
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 567 participants
- Where
- 4 sitesUnited States
- Study dates
- 5 May 2026to 15 Apr 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patient
- Age 0-12 years
- Diagnosed with any type or stage of cancer
- Receiving cancer directed treatment
- Parent
- Decision maker for the child.
Show all 9Show fewer
- Biological parent, step-parent, legal guardian (e.g., adoptive parent), or grandparent with medical consent authority.
- Has a child meeting the child inclusion criteria listed above.
- Able to communicate in English or Spanish (the languages of the video decision aids).
Who cannot join
- Patient
- Not receiving primary medical care from the cancer clinic (e.g., second-opinion consultations only)
- Already referred to and fully consulted by the palliative care team
- Prognosis of less than a 2-month life expectancy
- Parent
- Visually impaired beyond 20/200 corrected and unable to view the video (note: hearing impaired is not an exclusion as the videos are closed captioned).
- Psychological state not appropriate for GOC discussions, as determined by the primary oncologist per the opt-out.
- Participants who do not speak English or Spanish
Trial locations and contacts
4 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States4 sites, 3 recruiting
- Recruiting
Children's Hospital of Atlanta
Atlanta, Georgia, 30342
Katharine Brock, MD, katharine.brock@choa.org
Katharine Brock, MD
- Recruiting
Children's of Alabama at Birmingham
Birmingham, Alabama, 35233
Emily Johnston, MD, eejohnston@uabmc.edu
Emily Johnston, MD
- Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts, 02215
Jennifer Snaman, MD, 617-632-5548, jennifer_snaman@dfci.harvard.edu
Jennifer Snaman, MD
- Active, not recruiting
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756
About this study
Official title: A Multisite RWCT Comparing the Effectiveness of a Goals of Care Video and Navigator Intervention, the VIDEO-PEDS Experience, Versus Usual Care in Pediatric Cancer
The goal of this clinical trial is to learn if the VIDEO-PEDS intervention works to improve Goals of Care communication between clinicians and parents of children with cancer.
The main questions it aims to answer are:
Does the intervention improve Goals of Care documentation? Does it improve patient outcomes (including less invasive preferences for resuscitation and interventions, less hospital utilization, and more palliative care and hospice use)? Does it improve parent outcomes (including health satisfaction and feeling heard and understood per survey scores)?
Read the detailed description
Background
Parents of children with advanced cancer often face challenging decisions about goals of care (GOC) amidst high stress and limited understanding of medical interventions. Despite evidence that early and informed GOC discussions improve end-of-life experiences and align care with family values, such conversations remain infrequent in pediatric oncology. Barriers such as communication gaps, literacy challenges, and cultural differences exacerbate disparities, particularly among African American, Hispanic, and rural populations. The Video Images about Decisions for Ethical Outcomes in Pediatrics (VIDEO-PEDS) trial aims to address these gaps through an innovative video-based intervention. Similar interventions were effective in an adult cancer population.
Aims
- To refine and finalize a theory-based video decision aid tailored to parents of children with advanced cancer.
- To evaluate the feasibility, acceptability, and preliminary impact of the intervention through a pilot study.
- To conduct a randomized waitlist-controlled trial (RWCT) assessing the effectiveness of the intervention in improving GOC communication and documentation.
Design
This study will be conducted in two phases:
- Pilot Study
- Design: A mixed-methods study to test the feasibility and acceptability of the intervention among 27 parents (9 per site). Focus groups with 36 parents (12 per site) will be conducted in English and Spanish. Clinician providers will be interviewed.
- Purpose: To refine the intervention and ensure its appropriateness for the larger trial.
- Randomized Waitlist-Controlled Trial (RWCT)
- Design: A multicenter, parallel-group RCT with a waitlist control.
- Purpose: To evaluate the impact of the intervention on GOC documentation and patient- and parent-centered outcomes.
Setting
The study will take place across three diverse healthcare systems:
- Dana-Farber Cancer Institute/Boston Children's Hospital
- Children's Healthcare of Atlanta/Aflac Cancer Center
- University of Alabama at Birmingham These sites were selected because of their robust pediatric oncology programs and diverse patient populations, including African American, Hispanic, and rural families.
Participants/Subjects
- Pilot Study: Parents of 27 children (9 per site) aged 0-12 years with cancer will be recruited to test the intervention.
- RWCT:
- A total of 504 parents (168 per recruitment cycle across three cycles) will be enrolled.
- Stratification will ensure representation of African American, Hispanic, and rural populations.
Interventions
- Pilot Study:
- Intervention: A video decision aid coupled with structured conversations facilitated by trained Navigators. The video provides education about GOC, focusing on values-based decision-making and specific interventions (e.g., CPR, intubation).
- Duration: Parents will view the video and engage in one or more conversations with the Navigator over three months.
- RWCT:
- Intervention: Refined video decision aid with Navigator-led discussions over a nine-month period.
- Control: Usual care, with the intervention provided to the waitlist control group after nine months.
Methods Patients will be screened from oncology patient lists at the three enrolling sites. A research assistant will complete an eligibility checklist for all meeting general criteria after an initial screening. For those potentially eligible, an eligibility checklist will be reviewed by a site PI and validated (eventually through REDCap). Once deemed eligible, an opt-out email is sent to the primary clinician for permission to approach. Invitations will then be sent by mail or email, followed by an in-person or phone approach. Prospective verbal informed consent will be obtained from the parents who choose to participate. Participation then involves viewing the Video. Video cards (inexpensive disposable devices) may be provided to reduce barriers to participation. Following the viewing, an extensively trained Navigator from the research team will discuss the goals of care broadly with the parent throughout the study duration, prompting engagement with the primary oncologist.
Development Phase:
- Parent focus groups led by site PIs will be held in English and Spanish via Zoom and audio recorded. The video will be shown and discussed following a semi-structured guide.
- The video will be refilmed to incorporate feedback from the focus groups.
- Workflows will be refined and study infrastructure will be developed further for the next phase.
Pilot Study:
- An abbreviated 3-month version of the intervention will be tested, including pre- and post-study surveys.
RWCT:
The investigators will conduct a large, pragmatic, randomized, waitlist-controlled trial (RWCT). The investigators will conduct three cycles of nine months. Thus, over the course of 27 months, three cycles of unique patients will be randomized (9 months per cycle x 3 cycles = 27 months). The recruitment period is 36 months to account for the last nine months of intervention for Waitlist-Controls in the last cycle. At the start of each of the three cycles, the investigators will ask each health system to curate and finalize a list of all eligible patients. For each cycle, one-third of the total 504 (i.e., N=168) will be randomized in 1:1 assignment, stratified by health system and demographic characteristics (African American, Hispanic, and rural) to Waitlist-Control or GOC Video Intervention.
A subgroup of 136 parents (total) will be asked to complete a survey via REDCap. These parents will be evenly divided between the two arms of the study and the three study sites. Participants will receive a self-administered survey via email/mailing at the beginning of a nine-month period and again at the end.
A subgroup of 12 parents (total) will be asked to complete an audio-recorded exit interview. The investigators will ask parents to comment on the perceived usefulness of the intervention, whether anything was learned, and how communication may have changed with the participant's clinicians since the intervention.
A subgroup of 25 parents (total) will have the Navigator conversation audio-recorded for intervention fidelity. A subset of these will be transcribed and further analyzed.
Stakeholder Interviews will be conducted with 18 clinicians (6 per site) including key clinical leaders of services.
Data Analysis:
- Mixed-methods process evaluation will use the RE-AIM framework to assess implementation.
- Descriptive statistics will be used for feasibility outcomes (e.g., recruitment, and retention rates).
- Comparative analysis of primary and secondary outcomes between intervention and control groups using intention-to-treat principles.
- Natural Language Processing technology will be used to identify outcomes in the EHR.
Outcomes
While more detail on Outcomes exists in that section, the primary outcome for the RWCT is the presence of GOC documentation in the EHR. Secondary outcomes include:
- Implementation outcomes: Feasibility, acceptability, and fidelity of the intervention.
- Parent-reported outcomes: Satisfaction with communication, perceived knowledge, and decisional certainty.
- Patient outcomes: Location of care at the end of life, alignment of care with stated goals.
Exploratory analyses will examine subgroup effects among African American, Hispanic, and rural participants, as well as the cost-effectiveness and scalability of the intervention.
- Conditions
- Pediatric Cancer
- Being tested
- VIDEO-PEDS, VIDEO-PEDS pilot, Focus Group
- Keywords
- Advanced Care Planning, Palliative Care, End of Life
- Medical subject headings
- Neoplasms, Death
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VIDEO-PEDSOther
Following enrollment, parents will receive a link to view the refined video decision aid that is designed to prompt parents to think about their goals of care for their child with cancer, and then to react by engaging in communication with a trained member of the research team called the Navigator and eventually their clinical team over the course of the 9-month study duration.
VIDEO-PEDS pilotOther
This is the 3-month pilot version of the intervention, which will be further developed for the eventual RWCT.
Focus GroupOther
Parents will view the Video aid and provide fascilitated feedback in an audio-recorded virtual group setting.
| Study group | Role | What they receive |
|---|---|---|
| UH3 RWCT Arm - Intervention | Experimental | This group will receive the VIDEO-PEDS intervention. Receives: Other: VIDEO-PEDS |
| UH3 RWCT Arm - Control | No intervention | This group will receive usual care until the 9-month wait period expires. |
| UG3 Pilot Intervention | Other | This group will receive the 3-month pilot version of the VIDEO-PEDS intervention. Receives: Other: VIDEO-PEDS pilot |
| UG3 Focus Group | Other | This group will participate in the virtual parent focus groups. Receives: Other: Focus Group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Goals-of-Care Discussion
Percentage of parents who held conversations with their medical team about goals, values, or priorities for treatment and outcomes as per documentation in the medical record.
Measured: At the end of Cycles 1, 2, and 3 (each cycle is 9 months)
Code Status Limitation
Percentage of parents who communicate limitations to cardiopulmonary resuscitation and intubation with their medical team as per documentation in the medical record.
Measured: At the end of Cycles 1, 2, and 3 (each cycle is 9 months)
Palliative Care
Percentage of parents who mention a visit with a specialty palliative care clinician, mention of specialist palliative care discussion, or patient preferences regarding seeing a palliative care clinician to their medical team as per documentation in the medical record.
Measured: At the end of Cycles 1, 2, and 3 (each cycle is 9 months)
Time-Limited Trial
Percentage of parents who engage in conversations with their medical team about the use of a treatment or procedure for a set amount of time with a pre-defined goal and plan related to the outcome at the end of the trial as per documentation in the medical record.
Measured: At the end of Cycles 1, 2, and 3 (each cycle is 9 months)
Secondary outcomes (3)
Acceptability themes from qualitative data
For the development phase, qualitative group interviews will yield information about participant preferences. For the pilot phase, qualitative individual interviews will yield information about participant preferences after a 3-month study duration.
Measured: 2 years
Feasibility by % of parents
Feasibility will be assessed as ability to identify, recruit, and retain participants as a percentage. 70% of those screened should be eligible for approach after the Validation and Opt-out Steps. 70% approached should agree to participate. 70% should complete the study. (<30% should be lost to follow-up or withdraw from the study.)
Measured: 2 years
Parent Satisfaction scores
A parent survey will measure how parents felt heard and understood by the medical team and how satisfied they were with the care received using five validated items from the measure Feeling Heard and Understood and two items from the Survey about Caring for Children with Cancer (SCCC) all answered on a 5-point Likert Scale. Scores range from 0 to 100 with 0 being the lowest satisfaction.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jan 2025
- Study start5 May 2026
- Primary completion15 Jan 2030 (estimated)
- Study completion15 Apr 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Pediatric CancerStudies of the same condition, open and under way.
- More trials run by Massachusetts General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- The initial development and pilot phase is not randomized and the latter RWCT phase is 1:1 parallel randomized arms.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 567 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Massachusetts General Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI), Dartmouth-Hitchcock Medical Center, Dana-Farber Cancer Institute, Yale University, Emory University, Children's Healthcare of Atlanta, University of Alabama at Birmingham
- Responsible party
- Principal investigator, Joanne Wolfe, MD, MPH, Massachusetts General Hospital
- Investigators
- Angelo Volandes, MD, Principal investigator, Dartmouth-Hitchcock Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06786104
- Sponsor's protocol ID
- 24-313
- Other IDs
- 1UG3CA286852-01A1
- Acronym
- VIDEO-PEDS
- Status last verified
- May 2026
- First submitted
- 7 Jan 2025
- Last updated
- 14 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Volandes AE, Zupanc SN, Lakin JR, Cabral HJ, Burns EA, Carney MT, Lopez S, Itty J, Emmert K, Martin NJ, Cole T, Dobie A, Cucinotta T, Joel M, Caruso LB, Henault L, Dugas JN, Astone K, Winter M, Wang N, Davis AD, Garde C, Rodriguez PM, El-Jawahri A, Moseley ET, Das S, Sciacca K, Ramirez AM, Gromova V, Lambert S, Sanghani S, Lindvall C, Paasche-Orlow MK. Video Intervention and Goals-of-Care Documentation in Hospitalized Older Adults: The VIDEO-PCE Randomized Clinical Trial. JAMA Netw Open. 2023 Sep 5;6(9):e2332556. doi: 10.1001/jamanetworkopen.2023.32556.
PubMed 37695586Snaman JM, Feifer D, Helton G, Chang Y, El-Jawahri A, Volandes AE, Wolfe J. A Pilot Randomized Trial of an Advance Care Planning Video Decision Support Tool for Adolescents and Young Adults With Advanced Cancer. J Natl Compr Canc Netw. 2023 Jul;21(7):715-723.e17. doi: 10.6004/jnccn.2023.7021.
PubMed 37433434Feifer D, Helton G, Wolfe J, Volandes A, Snaman JM. Adolescents and young adults with cancer conversations following participation in an advance care planning video pilot. Support Care Cancer. 2024 Feb 17;32(3):164. doi: 10.1007/s00520-024-08372-y.
PubMed 38367086Lindsay ME, de Oliveira S, Sciacca K, Lindvall C, Ananth PJ. Harnessing Natural Language Processing to Assess Quality of End-of-Life Care for Children With Cancer. JCO Clin Cancer Inform. 2024 Sep;8:e2400134. doi: 10.1200/CCI.24.00134.
PubMed 39265122Johnston EE, Alvarez E, Saynina O, Sanders L, Bhatia S, Chamberlain LJ. Disparities in the Intensity of End-of-Life Care for Children With Cancer. Pediatrics. 2017 Oct;140(4):e20170671. doi: 10.1542/peds.2017-0671.
PubMed 28963112Lindvall C, Deng CY, Moseley E, Agaronnik N, El-Jawahri A, Paasche-Orlow MK, Lakin JR, Volandes A, Tulsky TAIJA. Natural Language Processing to Identify Advance Care Planning Documentation in a Multisite Pragmatic Clinical Trial. J Pain Symptom Manage. 2022 Jan;63(1):e29-e36. doi: 10.1016/j.jpainsymman.2021.06.025. Epub 2021 Jul 14.
PubMed 34271146
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multisite RWCT Comparing the Effectiveness of a Goals of Care Video and Navigator Intervention, the VIDEO-PEDS Experience, Versus Usual Care in Pediatric Cancer
- ClinicalTrials.gov ID
- NCT06786104
- Acronym / sponsor ID
- VIDEO-PEDS / 24-313
- Conditions
- Pediatric Cancer
- Keywords
- Advanced Care Planning, Palliative Care, End of Life
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 567 participants (estimated)
- Lead sponsor
- Massachusetts General HospitalUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI), Dartmouth-Hitchcock Medical Center, Dana-Farber Cancer Institute, Yale University, Emory University, Children's Healthcare of Atlanta, University of Alabama at Birmingham
- Study start
- 5 May 2026 (actual)
- Primary completion
- 15 Jan 2030 (estimated)
- Study completion
- 15 Apr 2030 (estimated)
- First posted
- 22 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if the VIDEO-PEDS intervention works to improve Goals of Care communication between clinicians and parents of children with cancer.
The main questions it aims to answer are:
Does the intervention improve Goals of Care documentation? Does it improve patient outcomes (including less invasive preferences for resuscitation and interventions, less hospital utilization, and more palliative care and hospice use)? Does it improve parent outcomes (including health satisfaction and feeling heard and understood per survey scores)?
Detailed description
Background
Parents of children with advanced cancer often face challenging decisions about goals of care (GOC) amidst high stress and limited understanding of medical interventions. Despite evidence that early and informed GOC discussions improve end-of-life experiences and align care with family values, such conversations remain infrequent in pediatric oncology. Barriers such as communication gaps, literacy challenges, and cultural differences exacerbate disparities, particularly among African American, Hispanic, and rural populations. The Video Images about Decisions for Ethical Outcomes in Pediatrics (VIDEO-PEDS) trial aims to address these gaps through an innovative video-based intervention. Similar interventions were effective in an adult cancer population.
Aims
- To refine and finalize a theory-based video decision aid tailored to parents of children with advanced cancer.
- To evaluate the feasibility, acceptability, and preliminary impact of the intervention through a pilot study.
- To conduct a randomized waitlist-controlled trial (RWCT) assessing the effectiveness of the intervention in improving GOC communication and documentation.
Design
This study will be conducted in two phases:
- Pilot Study
- Design: A mixed-methods study to test the feasibility and acceptability of the intervention among 27 parents (9 per site). Focus groups with 36 parents (12 per site) will be conducted in English and Spanish. Clinician providers will be interviewed.
- Purpose: To refine the intervention and ensure its appropriateness for the larger trial.
- Randomized Waitlist-Controlled Trial (RWCT)
- Design: A multicenter, parallel-group RCT with a waitlist control.
- Purpose: To evaluate the impact of the intervention on GOC documentation and patient- and parent-centered outcomes.
Setting
The study will take place across three diverse healthcare systems:
- Dana-Farber Cancer Institute/Boston Children's Hospital
- Children's Healthcare of Atlanta/Aflac Cancer Center
- University of Alabama at Birmingham These sites were selected because of their robust pediatric oncology programs and diverse patient populations, including African American, Hispanic, and rural families.
Participants/Subjects
- Pilot Study: Parents of 27 children (9 per site) aged 0-12 years with cancer will be recruited to test the intervention.
- RWCT:
- A total of 504 parents (168 per recruitment cycle across three cycles) will be enrolled.
- Stratification will ensure representation of African American, Hispanic, and rural populations.
Interventions
- Pilot Study:
- Intervention: A video decision aid coupled with structured conversations facilitated by trained Navigators. The video provides education about GOC, focusing on values-based decision-making and specific interventions (e.g., CPR, intubation).
- Duration: Parents will view the video and engage in one or more conversations with the Navigator over three months.
- RWCT:
- Intervention: Refined video decision aid with Navigator-led discussions over a nine-month period.
- Control: Usual care, with the intervention provided to the waitlist control group after nine months.
Methods Patients will be screened from oncology patient lists at the three enrolling sites. A research assistant will complete an eligibility checklist for all meeting general criteria after an initial screening. For those potentially eligible, an eligibility checklist will be reviewed by a site PI and validated (eventually through REDCap). Once deemed eligible, an opt-out email is sent to the primary clinician for permission to approach. Invitations will then be sent by mail or email, followed by an in-person or phone approach. Prospective verbal informed consent will be obtained from the parents who choose to participate. Participation then involves viewing the Video. Video cards (inexpensive disposable devices) may be provided to reduce barriers to participation. Following the viewing, an extensively trained Navigator from the research team will discuss the goals of care broadly with the parent throughout the study duration, prompting engagement with the primary oncologist.
Development Phase:
- Parent focus groups led by site PIs will be held in English and Spanish via Zoom and audio recorded. The video will be shown and discussed following a semi-structured guide.
- The video will be refilmed to incorporate feedback from the focus groups.
- Workflows will be refined and study infrastructure will be developed further for the next phase.
Pilot Study:
- An abbreviated 3-month version of the intervention will be tested, including pre- and post-study surveys.
RWCT:
The investigators will conduct a large, pragmatic, randomized, waitlist-controlled trial (RWCT). The investigators will conduct three cycles of nine months. Thus, over the course of 27 months, three cycles of unique patients will be randomized (9 months per cycle x 3 cycles = 27 months). The recruitment period is 36 months to account for the last nine months of intervention for Waitlist-Controls in the last cycle. At the start of each of the three cycles, the investigators will ask each health system to curate and finalize a list of all eligible patients. For each cycle, one-third of the total 504 (i.e., N=168) will be randomized in 1:1 assignment, stratified by health system and demographic characteristics (African American, Hispanic, and rural) to Waitlist-Control or GOC Video Intervention.
A subgroup of 136 parents (total) will be asked to complete a survey via REDCap. These parents will be evenly divided between the two arms of the study and the three study sites. Participants will receive a self-administered survey via email/mailing at the beginning of a nine-month period and again at the end.
A subgroup of 12 parents (total) will be asked to complete an audio-recorded exit interview. The investigators will ask parents to comment on the perceived usefulness of the intervention, whether anything was learned, and how communication may have changed with the participant's clinicians since the intervention.
A subgroup of 25 parents (total) will have the Navigator conversation audio-recorded for intervention fidelity. A subset of these will be transcribed and further analyzed.
Stakeholder Interviews will be conducted with 18 clinicians (6 per site) including key clinical leaders of services.
Data Analysis:
- Mixed-methods process evaluation will use the RE-AIM framework to assess implementation.
- Descriptive statistics will be used for feasibility outcomes (e.g., recruitment, and retention rates).
- Comparative analysis of primary and secondary outcomes between intervention and control groups using intention-to-treat principles.
- Natural Language Processing technology will be used to identify outcomes in the EHR.
Outcomes
While more detail on Outcomes exists in that section, the primary outcome for the RWCT is the presence of GOC documentation in the EHR. Secondary outcomes include:
- Implementation outcomes: Feasibility, acceptability, and fidelity of the intervention.
- Parent-reported outcomes: Satisfaction with communication, perceived knowledge, and decisional certainty.
- Patient outcomes: Location of care at the end of life, alignment of care with stated goals.
Exploratory analyses will examine subgroup effects among African American, Hispanic, and rural participants, as well as the cost-effectiveness and scalability of the intervention.
Study design
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 4
- Model description
- The initial development and pilot phase is not randomized and the latter RWCT phase is 1:1 parallel randomized arms.
| Arm | Type | Receives |
|---|---|---|
| UH3 RWCT Arm - Intervention | Experimental | Other: VIDEO-PEDSThis group will receive the VIDEO-PEDS intervention. |
| UH3 RWCT Arm - Control | No intervention | –This group will receive usual care until the 9-month wait period expires. |
| UG3 Pilot Intervention | Other | Other: VIDEO-PEDS pilotThis group will receive the 3-month pilot version of the VIDEO-PEDS intervention. |
| UG3 Focus Group | Other | Other: Focus GroupThis group will participate in the virtual parent focus groups. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (9 listed)
- Patient
- Age 0-12 years
- Diagnosed with any type or stage of cancer
- Receiving cancer directed treatment
- Parent
Key exclusion criteria (8 listed)
- Patient
- Not receiving primary medical care from the cancer clinic (e.g., second-opinion consultations only)
- Already referred to and fully consulted by the palliative care team
- Prognosis of less than a 2-month life expectancy
- Parent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VIDEO-PEDSFollowing enrollment, parents will receive a link to view the refined video decision aid that is designed to prompt parents to think about their goals of care for their child with cancer, and then to react by engaging in communication with a trained member of the research team called the Navigator and eventually their clinical team over the course of the 9-month study duration. | Other | UH3 RWCT Arm - Intervention |
| VIDEO-PEDS pilotThis is the 3-month pilot version of the intervention, which will be further developed for the eventual RWCT. | Other | UG3 Pilot Intervention |
| Focus GroupParents will view the Video aid and provide fascilitated feedback in an audio-recorded virtual group setting. | Other | UG3 Focus Group |
Primary outcome
Goals-of-Care Discussion
Time frame: At the end of Cycles 1, 2, and 3 (each cycle is 9 months)
Percentage of parents who held conversations with their medical team about goals, values, or priorities for treatment and outcomes as per documentation in the medical record.
Code Status Limitation
Time frame: At the end of Cycles 1, 2, and 3 (each cycle is 9 months)
Percentage of parents who communicate limitations to cardiopulmonary resuscitation and intubation with their medical team as per documentation in the medical record.
Palliative Care
Time frame: At the end of Cycles 1, 2, and 3 (each cycle is 9 months)
Percentage of parents who mention a visit with a specialty palliative care clinician, mention of specialist palliative care discussion, or patient preferences regarding seeing a palliative care clinician to their medical team as per documentation in the medical record.
Time-Limited Trial
Time frame: At the end of Cycles 1, 2, and 3 (each cycle is 9 months)
Percentage of parents who engage in conversations with their medical team about the use of a treatment or procedure for a set amount of time with a pre-defined goal and plan related to the outcome at the end of the trial as per documentation in the medical record.
3 secondary outcomes
Acceptability themes from qualitative data
Time frame: 2 years
Feasibility by % of parents
Time frame: 2 years
Parent Satisfaction scores
Time frame: 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2026.
- Background: PubMed 37695586Volandes AE, Zupanc SN, Lakin JR, Cabral HJ, Burns EA, Carney MT, Lopez S, Itty J, Emmert K, Martin NJ, Cole T, Dobie A, Cucinotta T, Joel M, Caruso LB, Henault L, Dugas JN, Astone K, Winter M, Wang N, Davis AD, Garde C, Rodriguez PM, El-Jawahri A, Moseley ET, Das S, Sciacca K, Ramirez AM, Gromova V, Lambert S, Sanghani S, Lindvall C, Paasche-Orlow MK. Video Intervention and Goals-of-Care Documentation in Hospitalized Older Adults: The VIDEO-PCE Randomized Clinical Trial. JAMA Netw Open. 2023 Sep 5;6(9):e2332556. doi: 10.1001/jamanetworkopen.2023.32556.
- Background: PubMed 37433434Snaman JM, Feifer D, Helton G, Chang Y, El-Jawahri A, Volandes AE, Wolfe J. A Pilot Randomized Trial of an Advance Care Planning Video Decision Support Tool for Adolescents and Young Adults With Advanced Cancer. J Natl Compr Canc Netw. 2023 Jul;21(7):715-723.e17. doi: 10.6004/jnccn.2023.7021.
- Background: PubMed 38367086Feifer D, Helton G, Wolfe J, Volandes A, Snaman JM. Adolescents and young adults with cancer conversations following participation in an advance care planning video pilot. Support Care Cancer. 2024 Feb 17;32(3):164. doi: 10.1007/s00520-024-08372-y.
- Background: PubMed 39265122Lindsay ME, de Oliveira S, Sciacca K, Lindvall C, Ananth PJ. Harnessing Natural Language Processing to Assess Quality of End-of-Life Care for Children With Cancer. JCO Clin Cancer Inform. 2024 Sep;8:e2400134. doi: 10.1200/CCI.24.00134.
- Background: PubMed 28963112Johnston EE, Alvarez E, Saynina O, Sanders L, Bhatia S, Chamberlain LJ. Disparities in the Intensity of End-of-Life Care for Children With Cancer. Pediatrics. 2017 Oct;140(4):e20170671. doi: 10.1542/peds.2017-0671.
- Background: PubMed 34271146Lindvall C, Deng CY, Moseley E, Agaronnik N, El-Jawahri A, Paasche-Orlow MK, Lakin JR, Volandes A, Tulsky TAIJA. Natural Language Processing to Identify Advance Care Planning Documentation in a Multisite Pragmatic Clinical Trial. J Pain Symptom Manage. 2022 Jan;63(1):e29-e36. doi: 10.1016/j.jpainsymman.2021.06.025. Epub 2021 Jul 14.
- Individual participant dataSharing planned: No
Related trials for Pediatric Cancer
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
RecruitingPhase 1/2
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Myelodysplastic Syndromes
RecruitingObservational study
Psychological Benefits of a Normalized Camping Experience for Children With Cancer
Pediatric Cancer
Active, not recruitingPhase 3
An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
RecruitingObservational study
The Decision To Enroll In Therapeutic Clinical Trials In A Pediatric Cancer Clinical Network
Knowledge, Attitudes, Practice
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Angelo Volandes, MD principal investigator
Dartmouth-Hitchcock Medical Center
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing VIDEO-PEDS, VIDEO-PEDS pilot and Focus Group in people with Pediatric Cancer, run by Massachusetts General Hospital at 4 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Joanne E Wolfe, MD (6177242911, jwolfe@mgh.harvard.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Goals-of-Care Discussion (time frame: At the end of Cycles 1, 2, and 3 (each cycle is 9 months)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06786104, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2026.